University of Aberdeen

abdn.ac.uk

Total trials

172

Active

31

Phase 3

2

Total enrollment

86,185

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 4 of 4 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Blood collection for genetic analysis1
Semaglutide administration plus dietary counselling and physical activity encouragement1
Semaglutide plus a personalised and supervised program of resistance and endurance training1
Sodium-glucose transport-2 (SGLT-2) inhibitors1

Next readouts

  • 2028-07-31
  • 2028-10-31
  • 2028-12-31

Top conditions

  • Healthy7
  • Asthma7
  • Obesity6
  • Breast Cancer6
  • Cardiovascular Disease5
  • Chronic Pain4
  • Takotsubo Cardiomyopathy4
  • Type 2 Diabetes4

Frequently asked questions about University of Aberdeen

How many clinical trials does University of Aberdeen have on ClinicalTrials.gov?
University of Aberdeen is listed as the lead sponsor on 172 clinical trials in ClinicalTrials.gov, 31 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Aberdeen's trials are in Phase 3?
2 of University of Aberdeen's trials are in Phase 3, spread across 4 active drug programs.
What therapeutic areas does University of Aberdeen focus on?
University of Aberdeen's most-studied conditions on ClinicalTrials.gov are Healthy, Asthma, Obesity, Breast Cancer, Cardiovascular Disease.
When are University of Aberdeen's next clinical trial readouts?
University of Aberdeen has 3 upcoming primary-completion readouts tracked here; the soonest is “Rebalancing the Fat Content of the Heart and Muscles”, expected around 2028-07-31.